What is the current valuation of the Kidney Stones Market as of 2026?

The Kidney Stones Market is valued at approximately 2700.0 USD Million in 2024. Read More

What is the projected market valuation for the Kidney Stones Market in 2035?

The market is projected to reach approximately 4531.69 USD Million by 2035. Read More

What is the expected CAGR for the Kidney Stones Market during the forecast period 2025 - 2035?

The expected CAGR for the Kidney Stones Market during the forecast period 2025 - 2035 is 4.82%. Read More

Which companies are considered key players in the Kidney Stones Market?

Key players in the market include Boston Scientific, Medtronic, Johnson & Johnson, and C.R. Bard. Read More

What are the primary types of kidney stones and their market valuations?

The primary types of kidney stones include Calcium Oxalate valued at 1350.0 to 2250.0 USD Million, Uric Acid at 810.0 to 1350.0 USD Million, Struvite at 360.0 to 600.0 USD Million, and Cystine at 180.0 to 300.0 USD Million. Read More

What treatment methods are available for kidney stones and their market values?

Treatment methods include Medication valued at 810.0 to 1350.0 USD Million, Surgery at 810.0 to 1350.0 USD Million, Extracorporeal Shock Wave Lithotripsy at 540.0 to 900.0 USD Million, and Ureteroscopy at 540.0 to 900.0 USD Million. Read More

What diagnostic methods are utilized in the Kidney Stones Market and their valuations?

Diagnostic methods include Ultrasound valued at 540.0 to 900.0 USD Million, CT Scan at 810.0 to 1350.0 USD Million, X-ray at 540.0 to 900.0 USD Million, and Urinalysis at 810.0 to 1350.0 USD Million. Read More

How do patient demographics influence the Kidney Stones Market?

Patient demographics, including Age Group valued at 540.0 to 900.0 USD Million, Gender at 450.0 to 750.0 USD Million, and Lifestyle Factors at 810.0 to 1350.0 USD Million, play a crucial role in market dynamics. Read More

What geographic distribution trends are observed in the Kidney Stones Market?

Geographic distribution is valued at approximately 900.0 to 1531.69 USD Million, indicating varying prevalence across regions. Read More

How does the competitive landscape of the Kidney Stones Market appear in 2026?

The competitive landscape appears robust, with major players like Stryker Corporation and Olympus Corporation actively participating in market growth. Read More

Kidney Stones Market

ID: MRFR/HC/1213-CR

117 Pages

Satyendra Maurya

Last Updated: May 15, 2026

Kidney Stone Market Research Report Information by Type (Calcium Oxalate Stones, Uric Acid, Struvite Kidney Stones, Cystine Stones, Calcium Phosphate Stones), Treatment Type (Medications, Extracorporeal Shock Wave Lithotripsy, Ureteroscopy, Percutaneous Nephrolithotomy), Diagnosis (Ultrasound, Intravenous Pyelography, CT scan, X-Ray, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Kidney Stones (USD Million) | |
  1. 4.1.1 Calcium Oxalate | |
  2. 4.1.2 Uric Acid | |
  3. 4.1.3 Struvite | |
  4. 4.1.4 Cystine |
2. 4.2 Healthcare, BY Treatment Method (USD Million) | |
  1. 4.2.1 Medication | |
  2. 4.2.2 Surgery | |
  3. 4.2.3 Extracorporeal Shock Wave Lithotripsy | |
  4. 4.2.4 Ureteroscopy |
3. 4.3 Healthcare, BY Diagnosis Method (USD Million) | |
  1. 4.3.1 Ultrasound | |
  2. 4.3.2 CT Scan | |
  3. 4.3.3 X-ray | |
  4. 4.3.4 Urinalysis |
4. 4.4 Healthcare, BY Patient Demographics (USD Million) | |
  1. 4.4.1 Age Group | |
  2. 4.4.2 Gender | |
  3. 4.4.3 Lifestyle Factors | |
  4. 4.4.4 Geographic Distribution |
5. 4.5 Healthcare, BY Region (USD Million) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Boston Scientific (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Medtronic (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Johnson & Johnson (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 C.R. Bard (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Cook Medical (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Olympus Corporation (JP) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Stryker Corporation (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Terumo Corporation (JP) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Karl Storz (DE) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
7. 6.4 US MARKET ANALYSIS BY TREATMENT METHOD |
8. 6.5 US MARKET ANALYSIS BY DIAGNOSIS METHOD |
9. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT METHOD |
12. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
16. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT METHOD |
17. 6.14 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
20. 6.17 UK MARKET ANALYSIS BY TREATMENT METHOD |
21. 6.18 UK MARKET ANALYSIS BY DIAGNOSIS METHOD |
22. 6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
24. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT METHOD |
25. 6.22 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
28. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD |
29. 6.26 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
32. 6.29 ITALY MARKET ANALYSIS BY TREATMENT METHOD |
33. 6.30 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
36. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT METHOD |
37. 6.34 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
45. 6.42 CHINA MARKET ANALYSIS BY TREATMENT METHOD |
46. 6.43 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
49. 6.46 INDIA MARKET ANALYSIS BY TREATMENT METHOD |
50. 6.47 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
53. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT METHOD |
54. 6.51 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD |
62. 6.59 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
65. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT METHOD |
66. 6.63 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
69. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD |
70. 6.67 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD |
74. 6.71 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
78. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD |
79. 6.76 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
82. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT METHOD |
83. 6.80 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD |
87. 6.84 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF KIDNEY STONES |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD |
104. 6.101 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF KIDNEY STONES, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF KIDNEY STONES, 2024 TO 2035 (USD Million) |
114. 6.111 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Million) |
116. 6.113 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million) |
118. 6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.2.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.2.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.3.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.3.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.4.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.4.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.5.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.5.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.6.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.6.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.7.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.7.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.8.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.8.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.9.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.9.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.10.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.10.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.11.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.11.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.12.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.12.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.13.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.13.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.14.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.14.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.15.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.15.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.16.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.16.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.17.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.17.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.18.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.18.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.19.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.19.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.20.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.20.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.21.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.21.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.22.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.22.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.23.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.23.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.24.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.24.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.25.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.25.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.26.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.26.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.27.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.27.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.28.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.28.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.29.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.29.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF KIDNEY STONES, 2026-2035 (USD Million) | |
  2. 7.30.2 BY TREATMENT METHOD, 2026-2035 (USD Million) | |
  3. 7.30.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
  4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Kidney Stones Market Segmentation

Kidney Stones Market By Type of Kidney Stones (USD Million, 2022-2035)

Calcium Oxalate
Uric Acid
Struvite
Cystine

Kidney Stones Market By Treatment Method (USD Million, 2022-2035)

Medication
Surgery
Extracorporeal Shock Wave Lithotripsy
Ureteroscopy

Kidney Stones Market By Diagnosis Method (USD Million, 2022-2035)

Ultrasound
CT Scan
X-ray
Urinalysis

Kidney Stones Market By Patient Demographics (USD Million, 2022-2035)

Age Group
Gender
Lifestyle Factors
Geographic Distribution

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”